Knowra Biopharmaceutical Biopharmaceutical A medicinal product made using biological sources or biotechnology. Examples include therapeutic proteins, monoclonal antibodies, vaccines, and gene therapies.
Recombinant DNA : DNA assembled from genetic material joined from different sources, often used to produce a chosen protein in cells. It lets manufacturers program cells to make therapeutic proteins such as insulin.
Therapeutic protein : A protein administered as a medicine to replace, supplement, or alter a biological function. Insulin and clotting factors illustrate protein-based medicines made with biological production methods.
Small-molecule drug : A medicine whose active ingredient is a comparatively small, chemically defined molecule. Small molecules are generally simpler to characterize and synthesize than complex biological products.
Upstream processing : The cultivation and management of cells or microorganisms before product recovery. It establishes the biological production conditions that determine yield and product attributes.
Monoclonal antibody : A laboratory-produced antibody population made of molecules that bind the same specific target. Monoclonal antibodies are a major class of targeted biopharmaceuticals.
Vaccine : A preparation that trains the immune system to recognize and respond to a pathogen or target. Some vaccines use recombinant proteins, viral vectors, or other biotechnology-derived components.
Generic drug : A version of an approved small-molecule medicine with the same active ingredient and demonstrated equivalence. The generic model does not transfer directly to complex biopharmaceuticals.
Downstream processing : The recovery, purification, and formulation of a product after biological production. Purification removes cells, contaminants, and unwanted product variants.
Cell culture : The growth of cells under controlled conditions outside an organism. Cultured cells commonly produce complex therapeutic proteins.
Gene therapy : A treatment that modifies, replaces, or introduces genetic material to address disease. It is a biopharmaceutical approach that acts through genetic material rather than a conventional active ingredient.
Show all 22